

Endocarditis - Pipeline Insight, 2021

<https://marketpublishers.com/r/E5F46BC7E7C3EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: E5F46BC7E7C3EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Endocarditis – Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Endocarditis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Endocarditis Understanding

Endocarditis: Overview

Endocarditis, also known as infective endocarditis, is the inflammation and infection of the inner lining of the heart and heart valves which is known as the endocardium. The condition takes place with the entry of infectious organisms, such as fungi or bacteria into the bloodstream, after which they settle in the heart.

"Endocarditis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endocarditis pipeline landscape is provided which includes the disease overview and Endocarditis treatment guidelines. The assessment part of the report embraces, in depth Endocarditis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is

given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endocarditis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Endocarditis R&D. The therapies under development are focused on novel approaches to treat/improve Endocarditis.

Endocarditis Emerging Drugs Chapters

This segment of the Endocarditis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endocarditis Emerging Drugs

Exebacase: ContraFect

Exebacase, also known as CF-301, is being developed by ContraFect for the first-in-class new treatment for patients with Staph aureus bacteriam including endocarditis. The Phase 2 trial of this drug showed positive results and the company plans to initiate Phase 3 trials soon. It has a rapid, specific and novel mechanism of action which targets the peptidoglycan wall of the Staph aureus bacteria. Further, many studies have also shown that Exebacase is highly effective against biofilms as well.

Further product details are provided in the report.....

Endocarditis: Therapeutic Assessment

This segment of the report provides insights about the different Endocarditis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Endocarditis

There are approx. 4+ key companies which are developing the therapies for

Endocarditis. The companies which have their Endocarditis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, ContraFect and others.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Endocarditis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endocarditis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endocarditis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endocarditis drugs.

Endocarditis Report Insights

Endocarditis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Endocarditis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Endocarditis drugs?

How many Endocarditis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endocarditis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Endocarditis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Endocarditis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

ContraFect

Basilea

Key Products

Exebacase

Ceftobiprole medocaril

Contents

- Introduction
- Executive Summary
- Endocarditis: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Endocarditis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Endocarditis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Endocarditis Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Exebacase: ContraFect
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products

Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Endocarditis Key Companies
Endocarditis Key Products
Endocarditis- Unmet Needs
Endocarditis- Market Drivers and Barriers
Endocarditis- Future Perspectives and Conclusion
Endocarditis Analyst Views
Endocarditis Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Endocarditis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Endocarditis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Endocarditis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/E5F46BC7E7C3EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E5F46BC7E7C3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970